Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

588
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
588
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

524
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
524
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

583
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
583
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

466
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
466
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

618
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
618
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

363
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2-infected cardiomyocytes exhibit upregulated necroptosis, but no evidence of mitochondrial permeability transition.

Journal of molecular and cellular cardiology plus·2026
Same author

Pregnancy-Associated Cardiomyopathy in a Late-Diagnosed Partial Hydatidiform Mole: A Case Report.

Case reports in obstetrics and gynecology·2025
Same author

Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation.

International journal of cardiology·2024
Same author

Electrophysiological Correlates of Reward Anticipation in Subjects with Schizophrenia: An ERP Microstate Study.

Brain topography·2023
Same author

Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.

Herz·2022
Same author

The hidden structure dependence of the chemical life of dislocations.

Science advances·2021

Related Experiment Video

Updated: Feb 10, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Peripartum cardiomyopathy.

T Koenig1, D Hilfiker-Kleiner1, J Bauersachs2

  • 1Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Herz
|May 17, 2018
PubMed
Summary
This summary is machine-generated.

Peripartum cardiomyopathy (PPCM) is a rare heart condition affecting women late in pregnancy or postpartum. Bromocriptine treatment shows promise in reducing PPCM morbidity and mortality.

Keywords:
BromocriptineCardiomyopathiesHeart failurePregnancy complicationsProlactin

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Related Experiment Videos

Last Updated: Feb 10, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Area of Science:

  • Cardiology
  • Obstetrics
  • Pharmacology

Background:

  • Peripartum cardiomyopathy (PPCM) is a rare, potentially fatal heart muscle disease affecting women during late pregnancy or postpartum.
  • Its incidence varies geographically, with an estimated 1 in 1000-1500 pregnancies in Germany affected.
  • PPCM presents with a spectrum of severity, from mild symptoms to acute heart failure and cardiogenic shock.

Purpose of the Study:

  • To review current knowledge on the etiology of Peripartum Cardiomyopathy.
  • To summarize disease-specific treatment options for PPCM.
  • To highlight the role of Bromocriptine in managing PPCM.

Main Methods:

  • Literature review of Peripartum Cardiomyopathy.
  • Analysis of PPCM etiology, focusing on prolactin's role.
  • Evaluation of Bromocriptine's efficacy in PPCM treatment.

Main Results:

  • PPCM etiology involves an oxidative stress-mediated 16-kDa prolactin fragment damaging heart cells.
  • Bromocriptine, a dopamine-receptor agonist, inhibits prolactin release.
  • Bromocriptine, alongside standard heart failure therapy, reduces PPCM morbidity and mortality.

Conclusions:

  • Understanding PPCM etiology has advanced, implicating a prolactin fragment.
  • Bromocriptine offers a targeted therapy for PPCM by blocking prolactin.
  • Disease-specific treatment with Bromocriptine improves outcomes for PPCM patients.